Preclinical Evaluation of an Integrin α_vβ₆-Targeted Photodynamic Therapy.

ABSTRACT: Photodynamic therapy (PDT) is a minimally invasive treatment in which an external light source activates an injected photosensitizer (PS) to generate reactive oxygen species, causing localized cell death. Although the first PDT received FDA approval in 1995, clinical adoption has been limited, in part due to the limited tumor selectivity of PSs. The goal of this study was to develop a PS with improved tumor selectivity by incorporating a targeting peptide that selectively binds to the integrin α_vβ₆. The integrin α_vβ₆ is an epithelial-specific cell-surface receptor that is overexpressed in several cancer types, with expression level often linked to poor overall survival. The integrin α_vβ₆ targeting peptide (ABM-5G) was conjug

SUBMITTER: Zhang H 

PROVIDER: S-EPMC12272554 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature